Adagene (ADAG) had its price target raised by Guggenheim from $9.00 to $10.00. They now have a "buy" rating on the stock.
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs [Yahoo! Finance]
Adagene announces pricing of $70M public offering of ADS [Seeking Alpha]
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)